adalimumab-adbm

adalimumab-adbm (CYLTEZO) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.

CYLTEZO is a marketed brand name for adalimumab-adbm. Check FDA Drugs@FDA for the current US label holder and prescribing information.

adalimumab-adbm has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.